Clinical Trial Details


Research Study Summary

Do You Have Moderate to Severe Rheumatoid Arthritis? Research Study RA0077


An international clinical research study is under way to evaluate and compare the safety and effectiveness of two approved drugs for people living with moderate to severe Rheumatoid Arthritis.

Qualified participants will receive study related medication and care at no cost. In order to participate in this study you must continue to take your Methotrexate as prescribed by your doctor. Other eligibility criteria will apply. You will receive compensation up to $50.00 per study visit.

To find out more about this clinical research study please contact MCRC at 214-424-0405 or on the web at

Patient Inclusion Criteria:
If you have RA, you may be eligible to participate in this important clinical research study. You may qualify to participate if you:

  • Are a man or woman at least 18 years of age
  • Have a confirmed diagnosis of Rheumatoid Arthritis, which is considered moderate to severe

Patient Exclusion Criteria:

  • Currently not taking Methotrexate.

To Learn more

CW ID: 181924
Date Last Changed: July 18, 2013

Clinical Trial Snapshot

Both Male and Female
18 and up
Overall Status
Facility Type
$50 and up


Metroplex Clinical Research Center
8144 Walnut Hill Lane Suite 810
Dallas, TX 75231
Phone: 214-424-0405

View Map

Research Center Information:

Metroplex Clinical Research Center

Volunteer for this Trial

If you would like to learn more about participating in this research study, please email the trial contact using the form below. We value your privacy and your information will only be used by the research center to contact you regarding this study.

DISCLAIMER: CenterWatch does not conduct clinical research. CenterWatch is a publishing company that posts clinical trials information on behalf of sponsor companies, contract research organizations, clinical research sites and other interested parties. This information is designed to help patients find clinical trials of interest and contact the research centers conducting the trials.